Vizsgálati helyszín
Sofia
Sofia, BulgáriaEU-13 felzárkózó országMég nincs intézményhez kötve
- 19futó vizsgálat
- 15lezárt vizsgálat
- 0a helyszín által az elmúlt 60 napban megerősített vizsgálat
- –nyelv nincs megadva
A helyszín még egy vizsgálatot sem erősített meg.
Futó vizsgálatok
Toboroz
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
NCT07851025· 3. fázis· Forrás
Toboroz
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
NCT07624305· 3. fázis· Forrás
Toboroz
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970· 3. fázis· Forrás
Toboroz
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658· 2. fázis· Forrás
Toboroz
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581· 2. fázis· Forrás
Fut, nem toboroz
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
NCT07222917· 2. fázis· Forrás
Toboroz
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738· 2. fázis· Forrás
Fut, nem toboroz
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136· 3. fázis· Forrás
Toboroz
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
NCT06727227· Forrás
Fut, nem toboroz
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779· 3. fázis· Forrás
Toboroz
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652· 3. fázis· Forrás
Fut, nem toboroz
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963· 3. fázis· Forrás
Fut, nem toboroz
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235· 3. fázis· Forrás
Fut, nem toboroz
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134· 3. fázis· Forrás
Fut, nem toboroz
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068· 3. fázis· Forrás
Fut, nem toboroz
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616· 3. fázis· Forrás
Fut, nem toboroz
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
NCT03043872· 3. fázis· Forrás
Fut, nem toboroz
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02542293· 3. fázis· Forrás
Fut, nem toboroz
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932· 3. fázis· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Kutatók
Ide még nem kötődik kutató.
Hibát jelzek